A Phase 1 interventional study of CKD-378, QD, PO in Type II Diabetes Mellitus, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-08.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
A clinical trial to evaluate the food effect of CKD-378
An open-label, randomized, single-dose, 2-sequence, 2-period, crossover, phase 1 study to evaluate the food effect on the pharmacokinetics and safety of CKD-378 in healthy volunteers
9,590 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.
This study's enrollment of 31 is below the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Those with a history of regular alcohol intake before the first administration of investigational product
Those who have following diseases
* Period 1: A single oral dose of 2 tablets(CKD-378) under fasting condition * Period 2: A single oral dose of 2 tablets(CKD-378) under fed condition
Drug: CKD-378, QD, PO
* Period 1: A single oral dose of 2 tablets(CKD-378) under fed condition * Period 2: A single oral dose of 2 tablets(CKD-378) under fasting condition
Drug: CKD-378, QD, PO
CKD-378, QD, PO
AUCt of CKD-378
Area under the concentration-time curve time zero to time
Time frame: Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 24, 32, 48 hours
Cmax of CKD-378
Maximum plasma concentration of the drug
Time frame: Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 24, 32, 48 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Jun 2024, 1 month.
Of 393 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 1 month is below that.
Counting every sponsor, half of 458 studies reached it within 7 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CKD-378
Chong Kun Dang Pharmaceutical →